Skip Navigation



NDT Advance Access published online on October 25, 2005
Nephrology Dialysis Transplantation, doi:10.1093/ndt/gfi221
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
21/2/355    most recent
gfi221v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Linthorst, G. E.
Right arrow Articles by Hollak, C. E. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Linthorst, G. E.
Right arrow Articles by Hollak, C. E. M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2005]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org
Received February 4, 2005
Accepted September 20, 2005

Original Articles

Home treatment for Fabry disease: practice guidelines based on 3 years experience in The Netherlands

Gabor E. Linthorst 1*, Anouk C. Vedder 1, Els E. Ormel 1, Johannes M. F. G. Aerts 2, and Carla E. M. Hollak 1

1 Internal Medicine/Clinical Haematology, Academic Medical Centre, Amsterdam, The Netherlands
2 Department of Biochemistry, Academic Medical Centre, Amsterdam, The Netherlands

* To whom correspondence should be addressed.
Gabor E. Linthorst, E-mail: g.e.linthorst{at}amc.uva.nl



  Abstract

Introduction. Recently, chronic supplementation with {alpha}-galactosidase A ({alpha}Gal A) has been approved as a treatment modality for Fabry disease. The aim of the current study was to investigate the feasibility of home therapy for Fabry disease during a follow-up of >3 years and to make a proposal for practice guidelines.

Methods. Based on experience in previous clinical trials, an algorithm for home treatment eligibility was developed. The number of successful and uneventful infusions was recorded, as well as adverse and infusion-associated events. The presence and titre of recombinant human (rh)-{alpha}Gal A antibodies were monitored every 3 months.

Results. Thirty of the 36 patients eligible for home treatment received a total of 1418 infusions at home (median 44 infusions, range 1-108), between March 2001 and July 2005. Mean age was 44.7 years (17-71). Seventeen patients receiving home treatment (57%) were male. The majority of patients (27 out of 30, 90%) undergoing home treatment received 0.2 mg/kg agalsidase {alpha} or {beta}. Six male patients developed an infusion-associated event, of which three developed these at home. All patients with an infusion-associated event were anti-rh-{alpha}Gal A IgG positive at 3 months, but three patients with rh-{alpha}Gal A antibodies did not develop side effects. Antibody titres between these patients did not differ. None of the events was life-threatening or necessitated urgent admission.

Conclusion. Home treatment with rh-{alpha}Gal A for Fabry disease with 0.2 mg/kg for males and both 1.0 and 2.0 mg/kg for females is feasible and safe, and reduces both the burden related to chronic intravenous therapy and health care costs. Whether this can also be applied for male patients treated with 1.0 mg/kg has not yet been determined.

Keywords: non-diabetic renal diseases; treatment.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 NDT PlusHome page
F. Barbey, O. Lidove, and A. Schwarting
Fabry nephropathy: 5 years of enzyme replacement therapy--a short review
NDT Plus, February 1, 2008; 1(1): 11 - 19.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.